Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.

Key facts

Study ID

NCT00788112

Run by

University of California, San Francisco

People needed

17

Starts

2009-07-01

Expected to finish

2015-08-11

Last updated by the study team

2017-08-07

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.